List view / Grid view
23 September 2011 | By Novartis
A Phase III study of Afinitor® (everolimus) tablets* met its primary endpoint of best overall angiomyolipoma response rate...
23 September 2011 | By Gilead Sciences, Inc.
CHMP, has adopted a positive opinion on the company's Marketing Authorisation Application for the once-daily single-tablet regimen, Eviplera(R)...
23 September 2011 | By Novo Nordisk
CHMP has adopted a positive opinion on the usage of Novo Nordisk’s basal insulin analogue, Levemir®...
23 September 2011 | By Novo Nordisk
CHMP has adopted a positive opinion on the extended use of Novo Nordisk’s basal insulin analogue, insulin detemir...
22 September 2011 | By Boehringer Ingelheim
Phase II clinical trial results...
21 September 2011 | By Sygnature Discovery Limited
Sygnature Chemical Services, has become Sygnature Discovery to better reflect its Integrated Drug Discovery Service-Offering...
21 September 2011 | By Boehringer Ingelheim
Once-daily Viramune® (nevirapine) prolonged-release has received approval...
21 September 2011 | By Sanofi Pasteur
The pre-clinical vaccine was developed by researchers at the University of California...
20 September 2011 | By Eli Lilly and Company
Observational study leads to systemic approach to improve minority enrollment...
20 September 2011 | By Bristol-Myers Squibb
Strategic agreement for Anti-PD-1 Antibody, BMS-936558/ONO-4538, and ORENCIA® (abatacept)...
19 September 2011 | By Roche
Data show greater understanding of disease pathways and personalising treatments...
19 September 2011 | By
Results from the REALMRK clinical study...
15 September 2011 | By kdm communications limited
Cavro® Omni Robot incorporated into Applied Photophysics’ new protein discovery solution...
15 September 2011 | By GSK
GlaxoSmithKline announced that it has formed a long term strategic partnership with McLaren Group...
13 September 2011 | By Pfizer
Eclipse, extended the expiration date of the subsequent offering period of its tender offer...
